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Understanding the molecular mechanisms underlying voltage-dependent gating in voltage-gated 
ion channels (VGICs) has been a major effort over the last decades. In recent years, changes in 
the gating process have emerged as common denominators for several genetically determined 
channelopathies affecting heart rhythm (arrhythmias), neuronal excitability (epilepsy, pain), or 
skeletal muscle contraction (periodic paralysis). Moreover, gating changes appear as the main 
molecular mechanism by which several natural toxins from a variety of species affect ion channel 
function. In this work, we describe the pathophysiological and pharmacological relevance of the 
gating process in voltage-gated K+ channels encoded by the Kv7 gene family. After reviewing 
the current knowledge on the molecular mechanisms and on the structural models of voltage-
dependent gating in VGICs, we describe the physiological relevance of these channels, with 
particular emphasis on those formed by Kv7.2–Kv7.5 subunits having a well-established role in 
controlling neuronal excitability in humans. In fact, genetically determined alterations in Kv7. 2  
and Kv7 .3 genes are responsible for benign familial neonatal convulsions, a rare seizure disorder 
affecting newborns, and the pharmacological activation of Kv7 .2/3 channels can exert antiepileptic 
activity in humans. Both mutation-triggered channel dysfunction and drug-induced channel 
activation can occur by impeding or facilitating, respectively, channel sensitivity to membrane 
voltage and can affect overlapping molecular sites within the voltage-sensing domain of these 
channels. Thus, understanding the molecular steps involved in voltage-sensing in Kv7 channels 
will allow to better define the pathogenesis of rare human epilepsy, and to design innovative 
pharmacological strategies for the treatment of epilepsies and, possibly, other human diseases 
characterized by neuronal hyperexcitability.
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In voltage-gated ion channels (VGICs), the third largest group of 
signal-transduction proteins (Wulff et al., 2009), the gating mecha-
nism is triggered by transmembrane voltage changes. Differences of 
only a few millivolts can dramatically modify the opening prob-
ability of VGICs, leading to the massive ion fluxes responsible for 
electrical signaling in excitable cells; depending on the specific cell 
type involved, electrical signaling is then translated in mechani-
cal force (as in muscle contraction or cell movement) or chemi-
cal signal generation (hormone and neurotransmitter release). 
Additional gating triggers for ion channels are changes in the 
chemical composition of the extracellular or intracellular environ-
ment (ligand-gated ion channels), in the mechanical force applied 
(mechanosensitive channels), or of the environmental temperature 
(temperature-sensitive channels). Noteworthy, such representation 
is overly schematic, as diverse gating mechanisms often synergize 
in ion channels under physiological or pathological conditions, as 
in Ca2+-dependent K+ channels, some of which are also sensitive 
to membrane potential changes, in voltage-gated channels also 
affected by the osmotic pressure, and in ligand-gated channels, 
also acting as temperature sensors.
An historicAl introduction to voltAge-dependent 
gAting
Signaling via changes in membrane potential and transmembrane 
ion fluxes is essential to life in all biological organisms, from bacte-
ria to humans. Most cellular functions are properly executed only 
within a narrow range of intracellular and extracellular concentra-
tion for each ion species; thus, evolution has spent a tremendous 
effort in overcoming the thermodynamic cost required to translocate 
charges across low dielectric media such as the lipid membranes and 
selecting the appropriate means to perform such delicate regulation. 
Ion channel proteins, by allowing highly regulated ion fluxes across 
cellular compartments separated by a lipid membrane, provide a 
solution to this problem. Schematically speaking, two main prop-
erties characterize ion channel function: the first one is the gating 
mechanism, namely their ability to sense the appropriate stimulus, 
the other being selectivity, namely their capacity to discriminate the 
ion species allowed to permeate. These two properties, although 
conceptually separate, are clearly linked in the operation cycle of 
ion channels, as the structural rearrangement accompanying gating 
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and their ability to assemble into heteromeric channels, VGKCs 
can be divided in 12 subfamilies, from Kv1 to Kv12 in the official 
IUPHAR channel name terminology (Gutman et al., 2003; Harmar 
et al., 2009). VGKCs are important regulators of cellular electrical 
excitability; indeed, an increase in the membrane conductance for 
K+ ions causes, in most cases, membrane hyperpolarization and 
reduces excitability.
Most Kv channels assemble as tetramers of subunits, each corre-
sponding to a single domain of VGNCs and Ca2+ channels (VGNCs 
and VGCCs, respectively). Each Kv channel subunit is characterized 
by the presence of six transmembrane segments (form S1 to S6) and 
intracellular N- and C-terminal regions of variable length which 
contain important regions controlling fast inactivation, tetrameri-
zation, association with accessory proteins, and post-translational 
regulation of the channels.
Within each subunit, helices S5 and S6 and their interconnecting 
loop form the conduction pore which contains the K+ selectivity 
filter and the internal gate localized at the C-terminal region of S6, 
while segments from S1 to S4 form the so-called voltage-sensing 
domains (VSD) arranged symmetrically around the pore.
the structurAl bAsis of permeAtion
Structural work performed on bacterial non-voltage-gated “inward 
rectifier” K+ (KIR) channels KcsA (Doyle et al., 1998), MthK (Jiang 
et al., 2002a,b), and KirBac1.1 (Kuo et al., 2003), whose mem-
brane core of each subunit only contains the regions correspond-
ing to the S5–S6 domain and the intervening linker, has provided 
a valuable structural model to explain the molecular mechanisms 
of ion permeation, selectivity, and pore opening/closing behavior. 
Structural work on a Kir chimera formed by joining the trans-
membrane portion of a bacterial Kir to the cytoplasmic portion of 
eukaryotic Kir3.1 (Nishida and MacKinnon, 2002), have revealed 
further details on the pore structure in KIR channels, with particu-
lar reference to the presence of a long cytoplasmic pore (Nishida 
et al., 2007) and its voltage-dependent block by intracellular cations 
(Xu et al., 2009). Indeed, the comparison of structural data from 
the MthK channel trapped in the open conformation, and chan-
nels crystallized in the closed conformation (KcsA and KirBac1.1) 
revealed possible structural changes that underlie pore opening in 
K+ channels. In KcsA and Kirbac1.1 the second transmembrane 
helices (TM2), corresponding to the S6 transmembrane segments 
in Kv channels, are almost parallel to the membrane plane and form 
a four-helix bundle near the intracellular membrane surface that 
occludes the ion conduction pathway; by contrast, in open MthK 
channels, the TM2 helices are bent at a glycine residue, highly con-
served in bacterial K+ channels and some eukaryotic Kv channels. 
This glycine residue has been proposed to serve as a gating hinge 
that allows TM2 to fluctuate between a closed and an opened con-
formation. However, this structure-based gating model, although 
appealing in its simplicity, does not entirely fit with the details 
of functional experiments in most VGKCs; to account for some 
of these discrepancies, it has been more recently proposed that a 
conserved PXP motif (where X is any amino acid), not present in 
bacterial K+ channels and located in S6 downstream of the glycine 
residue, acts as a flexible hinge that keeps the upper portion of S6 
relatively still, but allows the lower half of S6 to move, opening 
the pore by swiveling the blocking residues away from the central 
In VGICs, it has long been hypothesized, much before their 
molecular architecture was defined, that movement of charged par-
ticles (termed “gating charges”) within the membrane electric field 
was responsible for voltage-dependent activation of the conduct-
ance (Hodgkin and Huxley, 1952). In the squid axon, gating current 
experiments allowed a direct measurement of gating charge trans-
location in the membrane dielectric field during voltage-  sensing 
for voltage-gated Na+ (VGNCs; Armstrong and Bezanilla, 1973) 
and K+ (VGKCs; Bezanilla et al., 1982) channels.
Although these studies established the basic biophysical and 
theoretical principles underlying voltage-sensing in VGICs, a major 
breakthrough toward the elucidation of the molecular mechanisms 
involved came from the identification of the primary sequence 
of the first VGIC, namely the VGNCs from the electroplax of the 
Electrophorus electricus (Noda et al., 1984), soon followed by that for 
a voltage-gated Ca2+ channel (VGCCs) from rabbit skeletal muscle 
(Tanabe et al., 1987) and for a VGKCs channel from Drosophila 
(Papazian et al., 1987). These earlier studies revealed the existence 
of an amino acid stretch within the fourth putative transmembrane 
segment (S4), where from four to eight positively charged resi-
dues (K, lysines; R, arginines) were present at each third position, 
mostly separated by uncharged residues; such peculiar arrangement 
allowed to hypothesize that the charged elements located within 
the electric field along the transmembrane S4 segment represented 
the main gating charges of VGICs. In the following decade, exten-
sive testing and refinement of this original hypothesis by a wide 
variety of experimental approaches, mainly including mutagen-
esis, fluorescence spectroscopy, and electrophysiology, confirmed 
the role of the S4 positive charges in voltage-sensing, and allowed 
to elaborate a more complex picture of the gating process which 
also  involved  negatively  charged  residues  in  neighboring  seg-
ments, protein regions translating gating charge movement into 
pore opening, interacting lipids, cooperativity among different 
gating elements, and modulation by drugs and toxins (Bosmans 
and Swartz, 2010).
In  the  last  years,  mainly  due  to  structural  work  on  the 
  voltage-sensing region of several VGKCs performed by Roderick 
MacKinnon and his group, some of the molecular intimacies of 
voltage-sensing have been uncovered. Although these achievements 
have definitively provided a clearer mechanistic view of this process, 
several controversies are yet to be resolved and gaps in our molecu-
lar understanding are waiting to be filled-in. Moreover, the last 
decade has witnessed an explosion of interest in genetically inher-
ited diseases caused by mutations occurring in ion channel genes 
(channelopathies); these studies have revealed that phenotypically 
heterogeneous diseases affecting heart rhythm (arrhythmias), neu-
ronal excitability (epilepsy, pain), or skeletal muscle contraction 
(periodic paralysis) have an altered gating process of the VGICs 
affected as a common denominator.
moleculAr Architecture of voltAge-dependent K+ 
chAnnels
clAssificAtion And overAll structure
Among the VGIC extended super-family of genes, those encod-
ing for K+ channels constitute more than half, with over 78 genes 
encoding for K+ channel subunits in humans (Wulff et al., 2009). 
According to primary sequence homology of their protein products www.frontiersin.org  February 2011  | Volume 2  | Article 2  |  3
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in Shaker and similar eukaryotic Kv channels; as previously men-
tioned, this regions represents the gating hinge for pore opening. 
On the basis of these observations, it has been proposed that, upon 
membrane depolarization, S4 outward movement (see below), by 
pulling onto the S4–S5 linker, causes the bending of the S6 gating 
hinge to open the S6 intracellular helix bundle, leading to pore 
opening (Long et al., 2005a,b). A second contact interface between 
the S1 region of the VSD and the extracellular surface of the pore 
has been recently proposed to act as an anchor point for efficient 
transmission of VSD conformational changes to the pore’s gate 
(Lee et al., 2009).
moleculAr models of vsd movement during gAting
 The structural and functional advancements briefly reviewed have 
converged onto the concept that charged and uncharged residues 
in the VSD act as crucial gating elements; however, the exact struc-
tural rearrangements within the VSD upon voltage-sensing are not 
completely understood. In particular, current controversies revolve 
around the extent and direction of these rearrangements with 
respect to the transmembrane electric field, their precise coordi-
nation in time among each other (Catterall, 2010), and the position 
of the field with respect to the membrane (Ahern and Horn, 2004; 
Bezanilla, 2008). In general terms, three main conceptual models 
have been proposed (Borjesson and Elinder, 2008):
•	 The	helical screw or sliding helix model was originally proposed 
soon after the first primary sequences of ion channel proteins 
were  available,  and  following  mutagenesis  studies  revealing 
that the first four Rs in S4 carry most of the gating charge 
(Aggarwal and MacKinnon, 1996; Seoh et al., 1996). In this 
model, under resting (hyperpolarized) conditions S4 Rs are 
drawn toward the intracellular side of the membrane by the 
electrostatic potential, and form ion pairs with negatively char-
ged residues in neighboring S1, S2, and S3 segments. When the 
membrane is depolarized, the S4 helix rotates along its length 
(by 60°–180°) and, at the same time, translates along its axis 
by 5–15 Å to allow the transfer of the three arginine charges 
per subunit across the electric field (that is to say, the S4 moves 
outwardly by a length corresponding to about three α-helical 
turns). This model has been largely supported by the results 
from accessibility studies of cysteines positioned at various 
locations along the S4 segment to membrane impermeable 
reagents (cysteine accessibility method; Larsson et al., 1996; 
Yusaf et al., 1996); these experiments revealed that the top S4 
arginines are only accessible to intracellularly applied reagents 
when the VSD occupies its resting position, but become acces-
sible to extracellularly applied reagents upon VSD activation. 
Noteworthy, only a narrow region of S4 appears protected from 
cysteine-reacting compounds when the VSD is in its resting or 
activated configurations.
 In this model, to allow outward movement of the gating charges, 
several ion pairs involving positively charged and negatively charged 
residues would be formed and rearranged in a stepwise fashion 
during VSD activation. These interactions would be also favored by 
the fact that the S4 segments assumes a 310 α-helical conformation, 
in which hydrogen bonding would be formed between the N-H 
group of an amino acid and the C = O group of the amino acid 
axis (Webster et al., 2004). Differences in the magnitude of move-
ment of the lower end of S6 would also explain the large conduct-
ance difference between eukaryotic and prokaryotic K+ channels; 
in fact, larger movements would be required to sustain the high 
single-channel conductance of the MthK channels (about 220 pS), 
whereas the smaller size of the pore formed at the PXP gating hinge 
in Kv1.1 channels would be responsible for their 10 times lower 
conductance (about 20 pS).
the structurAl bAsis of voltAge-sensing
In Kv channels, pore opening is regulated by the VSD. The first 
crystal structure of a K+ channel containing a VSD was that of bacte-
rial KvAP (Jiang et al., 2003a); soon after this landmark result, the 
crystal structures of the mammalian Kv1.2 channel was described 
(Long et al., 2005a,b, 2007). As previously mentioned, within each 
VSD, the S4 segment contains several (in most cases from 4 to 8) 
positively charged arginines (Rs) or lysine (Ks) residues. The first 
four of these residues are believed to be the most important voltage-
sensing elements and their movement during voltage-sensing is 
thought to represent a major part of the gating charges giving rise to 
gating currents (Aggarwal and MacKinnon, 1996; Seoh et al., 1996). 
In Kv1.1 channels, the number of elementary charges per channel 
crossing the electric field is estimated to be about 13, correspond-
ing to about three elementary charges per subunit (Schoppa et al., 
1992). Positively charged amino acids in S4 are separated by 2–3 
uncharged residues, so that the positive charges are mostly localized 
on the same side of an α-helix, and interact with highly conserved 
negatively charged residues in the S1–S3 region within the mem-
brane, while the lipid head groups stabilize the interactions with 
charged residues located at the membrane surface (Schmidt et al., 
2006; Long et al., 2007). In particular, negatively charged residues 
in S1 (E247), S2 (E283 and E293 in Shaker), and S3 (D316) seem 
to play a key role in the stabilization of positively charged residues 
in S4 (Delemotte et al., 2010), also contributing to gating charge 
movements (Seoh et al., 1996).
The  VSD  can  be  considered  as  an  independent  functional 
domain that can be transplanted onto other proteins to confer volt-
age sensitivity (Tombola et al., 2006); indeed, the voltage-sensing 
phosphatase from Ciona intestinalis (Ci-VSP; Murata et al., 2005) 
is formed by a VSD linked to a phosphatase: this protein directly 
translates changes in membrane potential into changes of phos-
phoinositides turnover. Moreover, the proton-selective channel 
Hv1 has been shown to be formed by subunits containing only 
an isolated VSD, without a canonical S5–S6 pore (Ramsey et al., 
2006; Sasaki et al., 2006); this astonishing result provided definitive 
evidence for the ability of the VSD to also function as an ion con-
duction pathway in native channels, a result in line with previous 
mutagenesis experiments showing the existence of so-called gating-
pore currents (ω-currents) flowing through the voltage sensors of 
VGKCs (Starace et al., 1997; Starace and Bezanilla, 2004; Tombola 
et al., 2005, 2007).
coupling voltAge-sensing to pore opening
Efficient coupling of the VSD movement to pore opening appears 
to involve the S4–S5 linker which, when the VSD is in the resting 
state, is believed to be positioned close to the internal end of S6, 
below the highly conserved PVP motif of the neighboring subunit Frontiers in Pharmacology  |  Pharmacology of Ion Channel and Channelopathies  February 2011  | Volume 2  | Article 2  |  4
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recently, structural and functional data have led to the pro-
posal that the highly conserved phenylalanine residue in S2 
is close to R1 in the resting VSD configuration and to R5 in 
the active configuration; given that the distance between the 
α carbons of R1 and R5 is about 21 Å along and 18 Å perpen-
dicular to the membrane, and assuming that the S2 segment 
is rather rigid and poorly mobile, these data would argue in 
favor of a large movement of the paddle relative to the rest of 
the VSD during activation (Tao et al., 2010). When compa-
ring the structural data from KvAP with those of mammalian 
channels, some difference are evident, particularly regarding 
the tighter association of S3 with S4 possibly caused by the 
shorter length of the S3–S4 linker in the KvAP channel. Thus, 
the paddle model appears to specifically capture some featu-
res of KvAP gating, but appears by no means to be applicable 
to all VGKCs (Tombola et al., 2005). Moreover, it has also 
been pointed out that the paddle model appears incompa-
tible with a number of experimental evidence obtained in 
other VGKCs, leading to the hypothesis that the KvAP struc-
ture may represent a non-native state of the channel, possibly 
resulting from distortions caused by the crystallization pro-
cedure (Catterall, 2010).
voltAge-dependent K+ chAnnels of the Kv7 subfAmily
Among Kv channels, the Kv7 family encompasses five members 
(from Kv7.1 to Kv7.5), each showing a different tissue distribution 
and physiological role (Miceli et al., 2008a; Figure 1). Indeed, Kv7.1 
is manly expressed in the heart, pancreas, thyroid gland, brain, gas-
trointestinal tract, portal vein, and the inner ear. In cardiac   myocytes, 
in association with KCNE1, Kv7.1 underlies the slow component 
of IKs, a K+-selective current involved in the late phase of action 
potential repolarization. Kv7.2, Kv7.3, Kv7.4, and Kv7.5 show preva-
lently neuronal localization; homo- or hetero-tetrameric assembly 
of Kv7.2 and Kv7.3 subunits, with possible additional contribution 
from Kv7.4 and Kv7.5 subunits at specific neuronal sites, represents 
the molecular basis of the M-current (IKM), a slowly activating and 
deactivating K+
 current highly regulated by Gq/11-coupled receptors 
(Delmas and Brown, 2005). IKM regulates membrane excitability in 
the sub-threshold range for action potential generation, acting as a 
brake for neuronal firing; indeed, reduction of this current is often 
sufficient to increase neuronal excitability. Kv7.4 subunits are mainly 
expressed in cochlear and vestibular organs of the inner hear, as well 
as in central auditory pathways (Kubisch et al., 1999); more recent 
work has revealed expression of Kv7.4 subunits also in skeletal mus-
cle (Iannotti et al., 2010), as well as in visceral and vascular smooth 
muscle (Greenwood and Ohya, 2009). Kv7.5 expression, in addition 
to the brain, has been also detected in human adult skeletal muscle 
(Lerche et al., 2000; Schroeder et al., 2000), and, together with Kv7.1 
and Kv7.4, in vascular smooth muscle cells (Yeung et al., 2007).
The pathophysiological importance of these channels is empha-
sized by the fact that mutations in four of the five Kv7 genes are 
associated to different hereditary channelopathies in humans. In 
particular, mutations in Kv7.1 have been found in families affected 
by arrhythmogenic diseases such as dominant (the Romano–Ward 
syndrome)  and  recessive  (the  Jervell  and  Lange-Nielsen  syn-
drome) chromosome 11-linked form of the Long QT syndrome 
(Wang et al., 1996), and the short QT syndrome (Bellocq et al., 
three (rather than four as in conventional α-helical conformations) 
earlier residues (Long et al., 2007; Khalili-Araghi et al., 2010); thus, 
it seems as the role of the neighboring negative charges is not only 
to reduce the energetic cost of moving the gating charges across 
the bilayer, but also to shape the S4 segment to achieve its optimal 
positioning in a partially stretched and unwinded configuration.
•	 The	 transporter  model,  an  evolved  version  of  two  previous 
models of charge translocation, the “rotation in place” (Cha 
et al., 1999) and the “moving orifice” (Yang et al., 1996), is 
mainly based on results from mutagenesis experiments (histi-
dine-  or  cysteine-scanning  mutagenesis),  fluorescent  reso-
nance energy transfer, spectroscopy, and X-ray crystallography. 
In fact, the previously mentioned results obtained with the 
cysteine accessibility technique suggest that most S4 arginines 
are easily accessible to intracellularly or extracellularly applied 
water-soluble reagents, arguing in favor of their location in 
water-filled  protein  crevices.  The  X-ray  structures  of  Kv1.2 
(Long et al., 2005a) and of a chimeric channel in which the 
voltage-sensor paddle (corresponding to the S3b–S4 region) of 
Kv2.1 was transferred into the Kv1.2 subunit (Long et al., 2007) 
provided structural support to this hypothesis. According to 
this model, during activation S4 would mainly undergo rota-
tional movements without significant translational movements 
(2–4 Å); upon membrane depolarization, S4 arginines would 
move from a crevice in contact with the intracellular solution 
into another crevice in contact with the extracellular solution. 
A corollary to this model is the fact that the membrane electric 
field would be focused within a region of the protein of appro-
ximately 5–10 Å, considerably thinner than the lipid mem-
brane (∼30Å). The resting and activated positions of the VSD 
would be stabilized by ionized hydrogen bonds between the S4 
arginines and two negatively charged clusters: one facing the 
extracellular side of the membrane and provided by the S1 and 
S2 helices, and another closer to the intracellular membrane 
surface, involving the S2 and the S3a helices. These two clusters 
would be separated by a highly conserved phenylalanine resi-
due positioned in the middle of S2 (the so-called “phenylala-
nine gap or cap”), which would therefore act as a gating charge 
transfer center across which the S4 segment rotates during 
activation (Tao et al., 2010). The existence of water-filled cre-
vices in the VSD is also consistent with the notion that, under 
specific circumstances, gating-pore currents (ω-currents) can 
flow  through  the  voltage  sensors  of VGKCs  (Starace  et  al., 
1997; Starace and Bezanilla, 2004; Tombola et al., 2005, 2007).
•	 The	paddle model is mainly based on the crystal structure 
of the bacterial channel KvAP (Jiang et al., 2003a,b). In this 
structure, the VSD was found to be positioned parallel to 
the intracellular side of the membrane, assuming a confor-
mation  likely  representing  the  resting  state  of  the  sensor; 
however, the channel pore appeared to be in the open con-
figuration.  Despite  such  discrepancy,  the  model  suggested 
that S4 and part of S3 (S3b) form an helical hairpin, or pad-
dle, that freely moves by a large extent (15–20 Å) across the 
lipidic bilayer during each gating cycle. Avidin accessibility 
to biotin tethered to different VSD positions confirmed the 
notion that the paddle undergoes large movements within 
the membrane (Jiang et al., 2003b; Ruta et al., 2005). More www.frontiersin.org  February 2011  | Volume 2  | Article 2  |  5
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2004). More recently, single nucleotide polymorphisms in Kv7.1 
have been suggested to confer susceptibility to type two diabetes 
(Unoki et al., 2008). Mutations in Kv7.4 underlie a rare form of 
deafness (DFNA2), characterized by symmetric, predominantly 
high-frequency sensorineural hearing loss that is slowly progres-
sive across all frequencies (Kubisch et al., 1999).
Mutations in the genes encoding for Kv7.2 (Biervert et al., 1998; 
Singh et al., 1998) or Kv7.3 (Charlier et al., 1998) are responsible 
for benign familial neonatal seizures (BFNS), a rare autosomal-
dominant idiopathic epilepsy of the newborn (Bellini et al., 2010). 
BFNS is characterized by the occurrence of focal, multifocal, or gen-
eralized unprovoked tonic–clonic convulsions starting around day 
3 of post-natal life and spontaneously disappearing after few weeks 
or months (Plouin, 1994). Although neurocognitive development is 
normal in most BFNS-affected individuals, follow-up studies have 
revealed that seizures or other neurological or neuropsychiatric 
abnormalities can occur in up to 15% of the patients (Ronen et al., 
1993; Dedek et al., 2001; Coppola et al., 2003; Wuttke et al., 2007). 
BFNS-causing mutations are 10 times more likely to be found in 
Kv7.2 than in Kv7.3; all Kv7.3 mutations described to date are mis-
sense, whereas Kv7.2 mutations consist of truncations, splice site 
defects, or missense, non-sense, and frame-shift mutations, as well 
as sub-microscopic deletions or duplications (Heron et al., 2007; 
Soldovieri et al., 2007a). Kv7.2 mutations have been also detected 
in sporadic cases of benign neonatal seizures (Sadewa et al., 2008; 
Ishii et al., 2009; Miceli et al., 2009a).
gAting chAnges Are mAjor pAthogenetic 
mechAnisms for bfns
A mild decrease of IKM function appears sufficient to cause BFNS, 
and  haploinsufficiency  seems  to  be  the  primary  pathogenetic 
mechanism for both familial and sporadic forms of the diseases. 
In Kv7.2, most BFNS-causing mutations are localized either in the 
large C-terminal domain, a critical region for subunit assembly 
and channel regulation by intracellular molecules, and in the VSD. 
Functional analysis of Kv7 channel subunits carrying mutations 
causing BFNS has revealed several mechanisms by which these 
genetic alterations impair IKM function (Soldovieri et al., 2007a). 
Some mutations drastically decrease channel subunit expression, 
while others affect the intracellular trafficking (Soldovieri et al., 
Figure 1 | Kv7 channels structure, tissue distribution, human channelopathies, and disease target.Frontiers in Pharmacology  |  Pharmacology of Ion Channel and Channelopathies  February 2011  | Volume 2  | Article 2  |  6
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tive analysis of the effects on IKM gating has revealed that even 
slight (∼5 mV) decreases in voltage sensitivity of the steady-state 
activation process of the macroscopic currents, as it occurs in the 
Kv7.2 mutants E119G (in the S1–S2 linker; Wuttke et al., 2008) 
and S122L (in the S2 segment; Hunter et al., 2006), is sufficient to 
cause BFNS. Gating changes are also a hallmark of the functional 
consequences of mutations affecting residues positioned within 
the S4 transmembrane segment. Among these, three BFNS-causing 
mutations involve positively charged residues: R207W (Wuttke 
et al., 2007), R213W (Sadewa et al., 2008), and R214W (Castaldo 
et al., 2002). These positions correspond to the third (R3), fifth 
(R5), and sixth (R6) positively charged residues along the Kv7.2 
primary sequence; it is worth noticing that, similarly to all other Kv7 
subunits, Kv7.2 lacks of the positively charged residue correspond-
ing to R3 in Kv1 channels, which is instead replaced by a glutamine. 
These substitutions cause functional changes of different extent; 
while no functional data is yet available on the R5W substitution, 
neutralization of the charge at R3 (R207W) was associated with 
a marked reduction of channel voltage sensitivity; on the other 
hand, milder effects were observed with the R6 (R214W) substitu-
2006) and polarized targeting of Kv7.2 subunits (Chung et al., 2006). 
Other mutations, instead, alter the function of Kv7.2 subunits nor-
mally inserted into the plasmamembrane; among these, changes in 
gating properties have been suggested to play a major role in BFNS 
pathogenesis (Dedek et al., 2001; Castaldo et al., 2002; Soldovieri 
et al., 2007b), a result consistent with these mutations affecting 
residues located within the VSD (Table 1).
The fact that IKM gating changes can be responsible for human 
epilepsies provides strong support for the hypothesis that this cur-
rent is a crucial regulator of neuronal excitability in humans; to 
achieve such delicate functional role, a fine control of IKM gating 
properties within a precise range of membrane potential values is 
required. In general, small changes in the channels’ voltage depend-
ence,  particularly  at  sub-threshold  voltages  (between  −60  and 
−30 mV), can profoundly affect neuronal excitability; it has been 
estimated that a 4-mV negative or positive shift of the conductance 
versus voltage (G/V curves) can increase or decrease, respectively, 
the current size by two-folds (Borjesson and Elinder, 2008). As a 
matter of fact, despite variability among expression systems and 
electrophysiological protocols used in different studies, quantita-
Table 1 | Benign familial neonatal seizures-causing mutations localized in Kv7.2 VSD: overview of the available genetic, clinical, and functional data.
Amino acid 
change
Localization Additional clinical data 
(beside BFNS)
Functional effects reference
p.E119G S1–S2 linker Generalized clonic seizures Slight rightward shift in current voltage 
dependence in the sub-threshold region; 
Slight decrease in current activation kinetics
Wuttke et al. (2008)
p.S122L Febrile seizures in later life; 
seizures until 7 years
Rightward shift in current voltage dependence 
in the sub-threshold region; decrease in 
current activation kinetics
Hunter et al. (2006)
p.A196V S4 – Rightward shift in current voltage 
dependence; decrease in current activation 
kinetics; novel pre-pulse-dependence of 
current activation kinetics
Soldovieri et al. (2007b)
p.[A196V;L197P] – Rightward shift in current voltage-
dependence; decrease in current activation 
kinetics
Soldovieri et al. (2007b), Moulard 
et al. (2001)
p.R207W Myokymia Marked rightward shift in current voltage 
dependence; dramatic decrease in current 
activation kinetics
Dedek et al. (2001)
p.R207Q Myokymia (no BFNS) Rightward shift in current voltage 
dependence; decrease in current activation 
kinetics
Wuttke et al. (2007)
p.M208V Generalized seizures 
between 4 and 7 years
Small decrease in maximal current; increased 
rate of channel deactivation
Singh et al. (2003)
p.D212G Rightward shift in current voltage 
dependence; increased rate of channel 
deactivation
Miceli et al. (2009a)
p.R213W – – Sadewa et al. (2008)
p.R214W – Slight rightward shift in current voltage 
dependence; no effect on maximal current 
amplitude
Miraglia del Giudice et al. (2000), 
Castaldo et al. (2002)
p.H228Q S4–S5 linker – – Singh et al. (2003)www.frontiersin.org  February 2011  | Volume 2  | Article 2  |  7
Miceli et al.  Mutations and drugs acting on Kv7 .2 VSD
tution (Soldovieri et al., 2007b), involving a residue located at the 
N-terminal end of the S4 and conserved among all Kv7 members 
except for Kv7.3. Electrophysiological analysis of the functional 
changes  prompted  the  A196V  mutation  by  macroscopic  and 
  single-channel current recordings, revealed that channels incor-
porating Kv7.2 A/V mutant subunits showed a decreased sensitivity 
to voltage. Intriguingly, the A196V mutation introduced an unusual 
dependence of the macroscopic current activation kinetics upon 
the pre-pulse voltage, showing an acceleration of gating kinetics by 
pre-pulses at hyperpolarizing voltages. This phenomenon, which is 
opposite to that described over 50 years ago in the squid axon by 
Cole and Moore (1960), who observed that K+ current activation 
kinetics were delayed by pre-pulses to more negative membrane 
potentials, has been interpreted by postulating that more depolar-
ized pre-pulse potentials would allow mutant channels to prefer-
entially populate an energetically favorable conformation in which 
the voltage sensors would be trapped in the inactive position, thus 
delaying its displacement to the active state, and, consequently, 
channel opening. Given that the alanine residue is smaller and 
more polar that valine, it appears as the mutation interferes with 
hydrophobic interactions occurring in the membrane bilayer or 
in other protein regions.
Finally, it should be mentioned that most functional studies have 
been performed by means of macroscopic current measurements; 
these, although providing important information about disease 
pathogenesis, are clearly unfit to reveal detailed structural changes 
occurring during VSD movements. Gating current measurements, 
although technically very challenging, are beginning to be used to 
characterize more precisely wild-type and mutant Kv7 channels 
gating behavior (Miceli et al., 2009b).
An homology model of Kv7.2
Sequence identity between Kv7.2 and the Kv1.2/2.1 chimera is 
29%, and sequence similarity is 49%; these values are even higher 
when analysis is restricted to the VSD domain (see alignments 
in Figure 2). Based on this high degree of sequence homology, it 
seems plausible to predict an overall similar structural arrange-
ment of the charged residues within the VSD between the two 
channels, although one important difference is the lack of the 
positively charged residue corresponding to R3 in all members of 
the Kv7 family, in which the R is replaced by a neutral glutamine 
(Q). Therefore, to provide insight into the possible structural 
consequences of the described mutations in the VSD causing 
BFNS, we built a homology model of the Kv7.2 subunit using 
the crystal coordinates of the Kv1.2/Kv2.1 chimera (Long et al., 
2007). As previously discussed, the original crystal structure was 
obtained in the absence of transmembrane potential; thus, the 
model captures the VSD in the activated configuration (“up state”; 
Figure 3A). According to the previously discussed models, the 
VSD position is stabilized by ionized hydrogen bonds between 
the charged S4 Rs and the two clusters of negative charges. In 
particular, in the activated state, the positively charged residue 
at position 207 (corresponding to R4 in Figure 2) forms ionized 
hydrogen bonds with a negatively charged residue belonging to 
the external cluster (E130, E1 in Figure 2), whereas that at posi-
tion 210 (corresponding to R5 in Figure 2) is predicted to inter-
act with negative charges of the inner cluster (E140 in S2; D172 
tion. These data, consistent with the previously discussed models 
in which gating charges corresponded to the first four S4 Rs, sug-
gested that R3 in Kv7.2 (corresponding to R4 in Kv1.1) has a more 
central role in voltage-sensing when compared to R6; noteworthy, 
R6 appears the least-conserved of the six S4 Rs among VGKCs 
(Miceli et al., 2008b). Moreover, at the R3 position, very different 
functional effects were revealed when comparing the properties of 
the glutamine (Q, which has a size similar to R, but is missing the 
charge) versus tryptophan (W, a bulkier uncharged amino acid) 
substitution; in fact, Kv7.2 R3W channels displayed a more marked 
positive shift in the half-activation potential when compared to 
R3Q channels, together with a marked slowing in current activa-
tion kinetics; these data allowed to conclude that, in addition to 
charge, steric bulkiness also plays a relevant role at position R3; by 
contrast, at the R6 position, no significant functional difference 
was noted between homomeric channel carrying the R6Q or the 
R6W substitution.
In order to assess the contribution of each R residue in S4 to Kv7.2 
channels voltage-sensing, neutral glutamines (Q) were introduced 
to substitute each R individually (Miceli et al., 2008b). The results 
obtained suggest that, in Kv7.2 channels, neutralization of the posi-
tive charges at the N-terminal end of S4 stabilized the activated state 
of the voltage sensor, whereas positive charge neutralization at the 
C-terminal end of S4 favored the resting conformation. Interesting, 
neutralization of R2 (R201) was sufficient to cause a complete loss 
of voltage dependence, suggesting that this R residue is indispensa-
ble to stabilize the resting configuration of the VSD in Kv7.2.
One striking structural characteristic of Kv7 channels is the 
presence of a negatively charged residue (D212) located between 
R4 and R5 in S4. Recently, a mutation affecting this residue has 
been identified in a sporadic case of BFNS (D212G; Miceli et al., 
2009a). Electrophysiological results revealed that homomeric and 
heteromeric channels incorporating Kv7.2 subunits carrying the 
D212G mutation displayed a positive shift in their steady-state volt-
age dependence of activation, requiring larger depolarizations to 
become activated; these effects were not accompanied by significant 
changes in plasma membrane expression, selectivity for K+ over 
Na+ ions, and pharmacological blockade by TEA. Moreover, the 
quantitative effect of the mutation appeared linearly related to the 
number of mutant subunits incorporated into the channels. Kinetic 
analysis in homomeric channels formed by subunits carrying the 
D212G substitution revealed that the mutation failed to interfere 
with either the fast or the slow time constants of activation, or 
with their amplitude ratio, but rather increased the rate of chan-
nel closing, indicative of a marked stabilization of the closed state, 
an effect responsible for the decreased sensitivity to voltage of the 
steady-state activation process.
In addition to charged residues, hydrophobic residues in S4 are 
also known to be involved in voltage-dependent gating of VGKCs 
(Lopez et al., 1991; McCormack et al., 1991); noteworthy, the gat-
ing differences between Shaker (Kv1) and Shaw (Kv3) channels have 
been attributed to sequence differences with respect to S4 uncharged 
amino acids (Smith-Maxwell et al., 1998). Consistent with this, 
uncharged residues in S4 are also targets for BFNS-causing muta-
tions (Moulard et al., 2001; Singh et al., 2003; Soldovieri et al., 
2007b). Some intriguing features have been recently revealed upon 
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Analysis of the model suggests that in Kv7.2 the replacement of 
R207 with a neutral amino acid such as Q or W hampers its interac-
tion with the external cluster of negative charges (E130), destabilizing 
the activated configuration of the VSD, and providing a plausible 
explanation for the positive shift in the steady-state voltage depend-
ence of activations observed in these mutants. Furthermore, it seems 
possible to speculate that the presence of a bulkier W at this position 
would delay the movement of R207 across the phenylalanine gap more 
than the smaller Q residue, leading to a substantial slowing of R207W 
channels opening kinetics when compared to the R207Q mutant.
Moreover, within the S4–S5 linker of Kv7.2, two ionized hydro-
gen bonds are formed between the side chain of the D212 residue 
and the lysine residue at position 219 (K219); in fact, the carboxyl 
end of D212 closely interacts with the aminic group of the K219 
side chain (2.18 Å distance), as well as with the aminic group of 
the protein backbone (2.87 Å distance); furthermore, the carboxyl 
group on the protein backbone of the D212 residue can form a 
third polar interaction with the aminic group of the K219 side 
chain (3.15 Å distance). Analysis of our homology model suggests 
that the substitution of the D212 residue with a glycine would 
loosen the previously described interactions involving its lateral 
chain carboxyl group, preserving only the interaction between the 
backbone carboxyl group and the aminic group in the K219 residue. 
If these interactions are essential in keeping the VSD in its activated 
configuration, it seems therefore not surprising that their absence 
would cause the Kv7.2 channels carrying the D212G mutations to 
display a reduced opening probability and a decreased sensitivity 
to voltage (Miceli et al., 2009a).
in S3 according to Kv7.2 numbering; respectively E2 and D1 in 
Figure 2). The two clusters are separated by the S2 phenylalanine 
gap (Phe 137 in Kv7.2).
Despite the intrinsic uncertainty related to the lack of crystal 
coordinates for Kv channels VSDs captured in the resting (“down 
state”) configurations, we also attempted to built an homology 
model of the resting state configuration of Kv7.2 VSD based on 
the available literature data (Pathak et al., 2007). According to this 
model (Figure 3B), and as also hypothesized on the basis of bio-
chemical experiments using functional rescue complementation 
by coupled mutations (Papazian et al., 1995), response to cysteine-
reacting methanethiosulfonate reagents in mutant Shaker channels 
(Larsson et al., 1996) and, more recently, functional analysis of 
gating-pore currents in VSD mutants (Tombola et al., 2005), in 
the resting VSD configuration the negatively charged E1 residue 
in S2 would preferentially interact with the R1 in S4, rather than 
with R4 as previously described in the activated VSD configuration; 
moreover, the R2 residue would establish a novel interaction with 
the D1 residue in S3. These data suggest that, during the activation 
process, the S4 segment would slide upwardly because of the loss of 
the interaction of E1 and D1 with the positively charged residues at 
R1 and R2, respectively, which would instead be replaced by the R4 
and R5 residues. As a consequence, the R207 residue (R4) would 
flip up around the Phe 137 residue on its way toward the extracel-
lular side of the membrane. The role of this Phe residue (Phe233 in 
the Kv2.1 paddle-Kv1.2 chimera) in forming the extracellular lid of 
an occluded binding site in voltage sensors into which S4 positive 
charges bind has been recently revealed (Tao et al., 2010).
Figure 2 | Sequence alignment of the relevant VSD regions of VgKCs (http://www.ebi.ac.uk/Tools/emboss/align/); residues are colored according to the 
following scheme: magenta, basic; blue, acid; red, non-polar; green, polar.www.frontiersin.org  February 2011  | Volume 2  | Article 2  |  9
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anxiety, attention-hyperactivity disorders, mania (Andreasen and 
Redrobe, 2009), bipolar disease, and schizophrenia (Hansen et al., 
2008). In all these diseases, hyperpolarization of the resting mem-
brane potential and decreased action potential generation prompted 
by the activation of neuronal K+ currents in excitatory neurons, may 
result in an effective therapeutic strategy. Moreover, since Kv7 subunit 
expression has been also found in non-neuronal tissues such as the 
smooth muscle of blood vessels and several visceral organs, as well 
as in skeletal muscle, IKM/Kv7 channel activators may be of benefit in 
the treatment of other diseases such as urinary incontinence (Rode 
et al., 2010), systemic or pulmonary arterial hypertension (Morecroft 
et al., 2009), and skeletal muscle diseases (Iannotti et al., 2010).
retigAbine
Retigabine is the prototype IKM opener, and is currently under clini-
cal scrutiny as an anticonvulsant. Retigabine is a structural analog 
of Flupirtine (D-9998; trade name Katadolon®), a triaminopyridine 
successfully used in clinical practice in some European countries 
since 1984 as a centrally acting non-opioid analgesic also provided 
with muscle-relaxing and neuroprotective actions, but devoid of 
appreciable anti-inflammatory and antipyretic activity. Retigabine’s 
efficacy as an anticonvulsant has been assessed in several preclinical 
models as well as in phase I, II, and III clinical studies (reviewed in 
Barrese et al., 2010). Retigabine activates Kv7.2–Kv7.5 channels at 
concentrations 10–30 times lower than those affecting other ion 
channels. Activation of Kv7 channels by retigabine is consequent to a 
complex combination of two distinct biophysical effects: an hyper-
polarization shift of the voltage dependence of channel activation, 
and an increase of the channel maximal opening probability which 
leads to an enhancement of the macroscopic currents (Tatulian 
et al., 2001). Noteworthy, retigabine does not affect Kv7.1 channels, 
an important issue when considering the cardiac safety profile of 
this novel antiepileptic compound.
The entity of the hyperpolarizing shift induced by retigabine on 
the Kv7 current activation varies among channels formed by differ-
ent Kv7 subunits: it is maximal for Kv7.3 (−43 mV), intermediate 
for Kv7.2 (−24 mV), and smaller for Kv7.4 (−14 mV) homomeric 
channel (Tatulian et al., 2001). Moreover, in Kv7.5 homomeric chan-
nels, retigabine fails to alter the voltage dependence, but markedly 
increased the maximal amount of current irrespectively on the 
membrane potential (Dupuis et al., 2002). Kv7.4 channels show 
both the shift in voltage dependence opening probability, and the 
increase of the maximal conductance; by contrast, in the maximal 
amount of current elicited by strong depolarization Kv7.2 and Kv7.2/
Kv7.3 channels was not affected by retigabine.
These changes were accompanied by a variable degree of drug-
induced delay in channel closure (deactivation), suggesting that the 
primary molecular consequence of the interaction of retigabine 
with the channel protein was a stabilization of the channel pore in 
the open conformation.
The potency of retigabine in causing the activation of channels 
formed by distinct Kv7 subunits appears slightly different; in most 
instance, Kv7.2 and Kv7.3 show higher (EC50 < 1 μM) and Kv7.4 and 
Kv7.5 lower (EC50 > 1 μM) sensitivity to the drug. Nevertheless, 
since these differences are quantitatively rather small, retigabine is 
currently regarded as an IKM opener poorly selective for channels 
composed of Kv7.2–Kv7.5 subunits.
Kv7 chAnnel modulAtors: moleculAr heterogeneity 
And moleculAr sites of Action
phArmAcologicAl relevAnce of Kv7 chAnnels
Given the described functional relevance of IKM/Kv7 channels in a 
wide range of physiological processes, it is not surprising that they 
are currently considered as relevant targets for the pharmacological 
treatment of several human diseases.
In  particular,  Kv7.1  blockers  might  be  of  help  in  treating 
arrhythmias (chromanol-293B or L-768673; Salata et al., 2004), 
whereas blockers of neuronal IKM formed by Kv7.2–Kv7.5 subunits, 
such as linopiridine, have been proposed to ameliorate the cog-
nitive decline occurring in neurodegenerative diseases (Fontana 
et al., 1994); however, these drugs have either not been tested or 
have generated inconclusive results in humans. Therefore, in the 
last few years, research on most of Kv7 blockers has progressed 
rather slowly.
By contrast, considerable interest has recently grown around 
neuronal IKM/Kv7 channel activators, given the extensive preclinical 
results showing that they might be effective tools against migraine, 
epilepsy, neuropathic pain, and neuropsychiatric   disorders   including 
Figure 3 | An homology model for Kv7.2 channels. Both panels show side 
views of a single Kv7 .2 subunit at lower (left) and higher (right) magnification. 
(A) Shows the activated configuration of the subunit and the corresponding 
VSD, whereas (B) shows the resting state. Amino acids involved in 
intra-subunit ion pairs in either resting and activated VSD configurations are 
shown. The homology model of the activated VSD of the Kv7 .2 channel was 
generated as previously described (Miceli et al., 2008b); the resting state was 
derived from the corresponding model of the Kv1.2 channel described by 
Pathak et al. (2007).Frontiers in Pharmacology  |  Pharmacology of Ion Channel and Channelopathies  February 2011  | Volume 2  | Article 2  |  10
Miceli et al.  Mutations and drugs acting on Kv7 .2 VSD
ICA-27243 is a compound belonging to the chemical class of 
substituted benzamides which, in contrast to retigabine which only 
shows poor discrimination among channels formed by different 
Kv7 subunits, selectively increased the maximal conductance and 
shifted the steady-state activation curve toward more hyperpolar-
ized potentials in Kv7.2/Kv7.3 heterotetramers (EC50 of 0.4 μM). 
ICA-27243 exhibited little activity against Kv7.1 channels, while its 
potency on Kv7.4 or Kv7.3/Kv7.5 channels was 20-fold and >100-
fold lower than that on Kv7.2/Kv7.3 heterotetramers, respectively 
(Wickenden et al., 2008); moreover, ICA-27243 exhibited anti-
convulsant properties in preclinical models of seizures in rodents 
(Roeloffs et al., 2008).
Other  enhancers  of  Kv7-mediated  currents  include  BMS-
204352, originally developed as an opener of Ca2+- and VGKCs 
(Schrøder et al., 2001; Korsgaard et al., 2005), and the acryla-
mide compounds defined as (S)-1 (Bentzen et al., 2006) and 
(S)-2 (Blom et al., 2009). Although these molecules can activate 
channels formed by all neural Kv7 subunits (except Kv7.1, with 
or without KCNE1), they display a noticeably stronger action on 
channels formed by Kv7.4 subunits (BMS-204352), or on Kv7.4 
and Kv7.5 subunits [(S)-1 and (S)-2]. At variance with ZyPn, no 
additive effect on Kv7.4 current amplitude was observed when both 
retigabine and (S)-1 or BMS204352 were applied simultaneously 
(Bentzen et al., 2006).
Finally, the cysteine-alkylating agent N-ethylmaleimide (NEM) 
also has been shown to increase the currents carried by native 
and heterologously expressed Kv7 channels (Roche et al., 2002; Li 
et al., 2004), being active on Kv7.2, 7.4, or 7.5, but not on Kv7.1 and 
Kv7.3 channels. In sensitive channels, NEM-induced augmenta-
tion of the macroscopic current was mainly due to an increase 
in single-  channel open probability. Similarly, currents carried by 
Kv7.2, Kv7.4, and Kv7.5 channels (but not by Kv7.1 or Kv7.3 chan-
nels) were strongly potentiated by oxidative modification caused 
by H2O2 exposure (Gamper et al., 2006).
some iKm ActivAtors bind to the pore And the intrAcellulAr 
gAte regions of Kv7 chAnnels
Mutagenesis and modeling experiments have suggested that, in 
channels formed by drug-sensitive Kv7 subunits, retigabine binds 
to a hydrophobic pocket located between the cytoplasmic parts of 
S5 and S6 in the open channel configuration. Within this cavity, a 
tryptophan residue in the intracellular end of the S5 helix (W236 
in the Kv7.2 sequence) seems to play a crucial role (Schenzer et al., 
2005; Wuttke et al., 2005; Figure 4A); replacement of W236 with a 
smaller and less hydrophobic leucine residue (naturally present at 
the corresponding position in retigabine-insensitive Kv7.1 subunits) 
largely prevents retigabine-induced IKM activation. Using a refined 
chimeric strategy, other residues crucial for retigabine-induced 
channel activation of Kv7.2 have been identified: in particular, L243 
in S5, L275 in the pore, L299 and Gly301 (corresponding to the 
putative gating hinge in Long et al., 2005a,b) in the S6 segments 
of the neighboring subunit (according to Kv7.2 numbering; Lange 
et al., 2009; Figure 1; Table 1). Except for Leu275, all these amino 
acids are conserved among neural Kv7 subunits but are missing in 
cardiac Kv7.1 subunits. The conserved tryptophan residue within 
S5 is also a crucial structural element of the binding site for BMS-
204352 and (S)-1 in Kv7.2–Kv7.5 channels (Bentzen et al., 2006; 
Noteworthy, both retigabine and flupirtine show a small but con-
sistent inhibitory effect on native voltage-dependent K+ currents in 
both neurons (Rundfeldt, 1997) and smooth muscle cells (Yeung 
et al., 2008), particularly evident at higher drug concentrations 
(>10 μM), and more depolarized potentials (>0 mV). Although the 
pharmacological relevance of these observations is still undefined, 
these results are consistent with a “bimodal” mechanism of action 
for these drugs.
other iKm ActivAtors
The demonstration that retigabine, by activating neuronal IKM, can 
exert anticonvulsant activity, have led to an explosion of interest 
toward the identification of additional congeners acting as IKM acti-
vators (Miceli et al., 2008a). Among these, zinc pyrithione (ZnPy), 
a compound used for dandruff control and psoriasis treatment, 
has been demonstrated to enhance the activity of all Kv7 channels, 
except those formed by Kv7.3 subunits (Xiong et al., 2007). In sensi-
tive channels, ZnPy causes an increase of maximal open probability, 
a significant hyperpolarization shift of voltage dependence, and 
a marked deactivation rate reduction. Noteworthy, its agonistic 
action was non-competitive with that exerted by retigabine, giving 
rise to combinatorial effects when the two molecules were applied 
together (Xiong et al., 2008). In Kv7.1 channels, activation by ZnPy 
is occluded by the co-expression of the auxiliary subunit KCNE1 
(Xiong et al., 2008), a result suggestive of a mechanistic overlap 
between ZnPy- and KCNE1-induced Kv7.1 current potentiation.
Phenamates such as meclofenamic acid and diclofenac are well-
known and widely used non-steroidal anti-inflammatory drugs act-
ing as non-selective inhibitors of the cyclooxygenase COX-1 and 
COX-2. These compounds have been described to also act as openers 
of Kv7 channels and to show robust antiepileptic properties in vivo: 
indeed, similarly to retigabine, they shift leftward the voltage depend-
ence of Kv7.2/3 channel activation, decrease deactivation kinetics, and 
hyperpolarize the resting membrane potential in cultured cortical 
neurons (Peretz et al., 2005). Both compounds did not affect Kv7.1 
or Kv7.1 + KCNE1 channels activity. Kv7.2/3 channel activation by 
meclofenamic acid and diclofenac showed an EC50 of about 3 μM. 
Based on these findings, new diphenylamine carboxylate derivatives 
have been designed to dissociate the IKM-opening property from COX 
inhibition. Indeed, diclofenac derivatives with poor (NH6; Peretz 
et al., 2007b) or absent (NH29; Peretz et al., 2007a) COX-blocking 
activity were synthesized; these molecules reduced neuronal excit-
ability and/or showed anticonvulsant effects in murine models of 
seizures.  Similarly  to  meclofenamic  acid  and  diclofenac,  NH29 
increased Kv7.2 macroscopic currents, produced an hyperpolarizing 
shift of the activation curve and significantly reduced both activa-
tion and deactivation rates of Kv7.2 channels, while it failed to affect 
homomeric Kv7.1 and Kv7.1/KCNE1 channels. Electrophysiological 
recordings from hippocampal neurons showed that NH29 power-
fully depressed synaptic transmission and inhibited glutamate and 
GABA release (Peretz et al., 2010), a result similar to that observed 
with retigabine (Martire et al., 2004). Noteworthy, diclofenac has 
been recently shown to act also as an activator of homomeric Kv7.4 
channels with an EC50 ∼ 100 μM, and an inhibitor of homomeric 
Kv7.5 channels with an intermediate IC50 (∼20 μM), being therefore 
the first compound to allow functional discrimination between these 
two channels subtypes (Brueggemann et al., 2011).www.frontiersin.org  February 2011  | Volume 2  | Article 2  |  11
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Blom et al., 2009), a result consistent with the lack of functional 
additivity observed when these compounds are applied together 
with retigabine.
Electrophysiological and mutagenesis experiments identified a 
binding site for ZnPy partially distinct from that of retigabine; 
in fact, ZnPy binds the extracellular side of the S5–S6 region: in 
particular, residues L249, L275, and A306 seem to be involved in 
the formation of binding site (Xiong et al., 2007). Residue L249 is 
localized in the S5 segment, while L275 in the pore loop, near to the 
selectivity filter; the position of the two residues may explain the 
increase of the open probability caused by the interaction of ZnPy 
with Kv7 channels. Moreover, residue A306 is localized between 
G301 and the conserved Pro-Ala-Gly sequence in the S6 domain. 
The location of these residues in the channel structure is consistent 
with the hypothesis that ZnPy stabilizes the open conformation.
The ability of retigabine and other IKM activators to bind to an 
hydrophobic pocket contributed by S5 and S6 and accessible from 
the cytoplasm in the open channel configuration is reminiscent of 
the high affinity use-dependent binding site for local anesthetics 
and antiarrhythmic drugs in VGNCs (Sheets et al., 2010), as well as 
of the Ca2+-antagonists of the phenylalkylamine and dihydropyrid-
ine chemical group on VGCCs (Mitterdorfer et al., 1998).
A novel binding site in the vsd for Kv7 ActivAtors
In addition to sites in S5 and S6, the VSD has also been identified 
as a receptor site for compounds acting as gating modifiers. As 
recently reviewed (Catterall et al., 2007; Swartz, 2007; Borjesson 
and Elinder, 2008), six distinct neurotoxin receptor sites have 
been identified in VGNCs. Toxins acting at receptor sites within 
the VSD (S3–S4 loop and N-terminal end of S4) in VGNCs are 
presumed to act by a voltage-sensor trapping mechanism to alter 
channel gating; more specifically, site 3-acting toxins (α-scorpion 
toxins, sea-anemone toxins, and some spider toxins known to 
slow or block sodium channel inactivation) would stabilize the 
resting configuration of the VSD, whereas toxins acting at site 4 
(β-scorpion toxins and some spider toxins, both shifting the voltage 
dependence of sodium channel activation in the   hyperpolarizing 
  direction and reducing the peak sodium current amplitude) would 
enhance activation by holding the S4 segment in domain II in its 
activated configuration.
In more general terms, it has been proposed that a voltage-sensor 
trapping mechanism may explain the actions of polypeptide toxins 
that alter the voltage dependence of gating in most voltage-gated 
channels. In fact, toxin-induced channel activation by a sensor trap-
ping mechanism can also occur in VGCCs (agatoxins from spiders), 
and in VGKCs of the Kv2 and Kv4 (hanatoxins from tarantula; Swartz 
and MacKinnon, 1997), or Kv3 and Kv11 (sea-anemone toxins; 
Diochot and Lazdunski, 2009) subclasses. It has been reported that 
a conserved structural motif in VGCCs and VGKCs can account for 
the “promiscuity” of both hanatoxin and grammotoxin (another 
tarantula toxin) to interact with both channel classes (Li-Smerin 
and Swartz, 1998), and, possibly, with non-voltage-gated channels 
of the TRPV1 subfamily (Siemens et al., 2006).
The existence in Kv7 channels of a molecular site of action for 
IKM activators distinct from that of retigabine was first hinted by 
the results from structure-function experiments showing that the 
replacement of the tryptophan residue at position 236 in Kv7.2 
channels, while largely abolishing the effect of retigabine, failed to 
affect current potentiation by phenamates (meclofenamic acid and 
diclofenac; Miceli et al., 2008a). The fact that phenamates acted at 
sites distinct from those occupied by retigabine was also consistent 
with the additivity shown by phenamates and retigabine in func-
tional experiments on Kv7.2/Kv7.3 channels (Peretz et al., 2005). 
More recently, the diphenylamine carboxylate derivative NH29 
(Peretz et al., 2007a), an analog of diclofenac, has been shown to 
activate Kv7.2 channels in both closed and open states by targeting 
the extracellular region of the VSD at the interface of helices S1, S2, 
and S4 (Peretz et al., 2010). In particular, within this region, NH29 
interacts with residues L197, R198, R207, and R214 localized in 
the S4 segment (Figure 4B). In addition to site-specific mutagen-
esis and electrophysiological experiments, docking data suggested 
that, in the open state, NH29 stabilizes the salt bridge between the 
guanidinium group of the third arginine residue of the S4 segment 
and the carboxylate group of E130 (in S2), a feature similar to that 
Figure 4 | An homology model for drug binding to Kv7.2 channels. Top view of 
the overall structure of the channel formed by four identical Kv7 .2 subunits (A), and 
enlarged view of a single Kv7 .2 subunit (B) captured in the activated configuration. 
The residues involved in binding of retigabine (indicated in orange), zinc pyrithione 
(indicated in yellow), and NH29 (indicated in green) highlighted. The L275 residue in 
the pore, common to both retigabine and zinc pyrithione binding, is indicated in 
violet. The S1 region has been removed for clarity. The homology model of the Kv7 .2 
channel was generated as previously described (Miceli et al., 2008b).Frontiers in Pharmacology  |  Pharmacology of Ion Channel and Channelopathies  February 2011  | Volume 2  | Article 2  |  12
Miceli et al.  Mutations and drugs acting on Kv7 .2 VSD
Andreasen, J. T., and Redrobe, J. P. (2009). 
Antidepressant-like effects of nicotine 
and mecamylamine in the mouse 
forced swim and tail suspension 
tests: role of strain, test and sex. Behav. 
Pharmacol. 20, 286–295.
Armstrong,  C.  M.,  and  Bezanilla, 
F.  (1973).  Currents  related  to 
  movement of the gating particles of 
the sodium channels. Nature 242, 
459–461.
Barrese, V., Miceli, F., Soldovieri, M. V., 
Ambrosino, P., Iannotti, F. A., Cilio, 
M. R., and Taglialatela, M. (2010). 
Neuronal potassium channel openers 
in the management of   epilepsy-role 
references
Aggarwal, S. K., and MacKinnon, R. 
(1996). Contribution of the S4 seg-
ment to gating charge in the Shaker 
K+ channel. Neuron 16, 1169–1177.
Ahern, C. A., and Horn, R. (2004). Stirring 
up controversy with a voltage sensor 
paddle. Trends Neurosci. 27, 303–307.
and potential of retigabine. Clin. 
Pharmacol. Adv. Appl. 2, 225–236.
Bellini, G., Miceli, F., Soldovieri, M. V., 
Miraglia del Giudice, E., Pascotto, 
A.,  and  Taglialatela,  M.  (2010). 
“Benign familial neonatal seizures,” 
in GeneReviews [Internet], eds R. A. 
Pagon, T. C. Bird, C. R. Dolan, and K. 
Table 2 | residues presumably involved in binding different iKM activators.
Drugs  Binding site  reference
Retigabine  W236 (S5), L243 (S5), L275 (pore), L299 (S6 of the   Wuttke et al. (2005), Schenzer et al.   
  neighboring subunit), and G301 (S6)  (2005), Lange et al. (2009)
Zinc pyrithione  L249 (S5), L275 (pore), and A306 (S6)  Xiong et al. (2007)
Diphenylamine carboxylate derivate NH29  K120 (loop S1–S2), Y127 (S2), E130 (S2), L197 (S4),   Peretz et al. (2010) 
  R198 (S4), L200 (S4), R207 (S4), and R214 (S4)
ICA-27243  S1-S4 transmembrane domain  Padilla et al. (2009)
Acrylamide derivate (S)-1  W242 (S5; according to Kv7 .4 numbering)  Bentzen et al. (2006)
BMS-204354  W242 (S5; according to Kv7 .4 numbering)  Bentzen et al. (2006)
NEM (N-ethylmaleimide)  C242 (S5); C519 (C-terminal; according to Kv7 .4 numbering)  Li et al. (2004), Roche et al. (2002)
H2O2  C150 to C153   Gamper et al. (2006)
described for tarantula toxins in the capsaicin receptor TRPV1 
(Siemens et al., 2006) and in other Kv channels (Swartz, 2007); by 
stabilizing the interaction between E130 in S2 and R207 in S4, NH29 
would favor the activated VSD configuration, thus leading to the 
described activation of Kv7.2 channels. On the other hand, in the 
closed state the compound would preferentially interact with the 
first arginine (R198) of the S4 segment.
Finally, the S1–S4 VSD also seems to represent the molecular site 
of action for ICA-27243 (Wickenden et al., 2008), another rather 
selective Kv7.2/3 activator exhibiting little activity against either 
Kv7.4 or Kv7.1 channels. However, within this region, specific amino 
acids involved in drug binding have not yet been identified (Padilla 
et al., 2009).
A summary of the residues involved in binding distinct IKM acti-
vators is shown in Table 2.
conclusion
When compared to voltage-dependent K channels of the Kv1–4 
subclasses which have been in the spotlight for over 20 years, 
Kv7 channels have only recently gained centre-stage attention. 
Although voltage-dependent currents having peculiar biophysical 
and neurochemical properties (slow activation and deactivation 
kinetics, lack of inactivation, regulation by Gq-linked neurotrans-
mitter receptors) have been known for quite some time and vari-
ably named and classified in various tissues (IKs in the heart, IKM 
in neurons, IKx in photoreceptors, IKn in hair cells), their molecular 
basis have remained elusive until the genetic basis of monogenic 
channelopathies such as the long and short QT syndromes, BFNS, 
and some rare forms of dominantly inherited deafness had been 
successfully identified. A solid (yet incomplete) description has 
followed showing that subunits encoded by distinct members of 
the Kv7 gene subfamily represent the molecular basis of each of 
these currents. Based on such seminal discoveries, Kv7 channels are 
currently considered as relevant targets for drugs currently being 
developed to dissect the functional relevance of each of the five 
Kv7 channel genes in distinct tissues, and to treat a wide array of 
human diseases, ranging from arrhythmias to pain states.
In this scene, understanding the distinct molecular sites on Kv7 
channels responsible for the action of modulators and for the effects 
of disease-causing mutations will unveil the molecular pathogenesis 
of these channelopathies, identify other pharmacophoric structures, 
and lead to a better picture of the complex structural rearrange-
ments accompanying channel function. In particular, the fact that, 
in the VSD of Kv7.2, some of the residues affecting drug-induced 
IKM activation also represent crucial gating residues targeted by 
BFNS-causing mutations suggests that this region acts not only 
as a major molecular determinant for disease pathogenesis, but 
also for potential pharmacological intervention against epilepsy. 
Since BFNS is a rather benign disease, most affected neonates do 
not require pharmacological intervention; nevertheless, the fact 
that the same mutations responsible for BFNS can cause resistance 
to IKM activators should be taken into account. In fact, the role of 
IKM in neuronal excitability control appears particularly relevant 
in the early phases of life (Okada et al., 2003; reviewed in Barrese 
et al., 2010), and it has been proposed that IKM openers can over-
come some of the limitations associated to anticonvulsants com-
monly used as first-line drugs in neonates (usually phenobarbital 
and phenytoin; Olney et al., 2004). Thus, the ability of different 
drugs to activate IKM by binding to different regions of the Kv7.2 
molecule might, at least in principle, allow an individually tailored 
and genotype-specific pharmacological treatment for BFNS.
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